Monitoring Inflammation in Cystic Fibrosis Patients
Author Information
Author(s): B. Niggemann, T. Stiller, K. Magdorf, U. Wahn
Primary Institution: University Children's Hospital (KAVH), Virchov-Klinikum of Humboldt University, Berlin, Germany
Hypothesis
Can myeloperoxidase (MPO) and eosinophil cationic protein (ECP) be used as parameters for monitoring inflammation in cystic fibrosis patients during antibiotic treatment?
Conclusion
MPO and neutrophil counts in peripheral blood correlate with clinical parameters, but sputum measurements of inflammation mediators are not recommended.
Supporting Evidence
- Modified Shwachman-Kulczycki score improved significantly during antibiotic treatment.
- C-reactive protein levels decreased significantly during antibiotic treatment.
- Serum MPO concentration and peripheral blood neutrophil counts decreased significantly during antibiotic treatment.
Takeaway
Doctors studied 10 cystic fibrosis patients to see if certain proteins in their blood could help track inflammation during treatment. They found some useful information, but not everything worked as expected.
Methodology
Ten cystic fibrosis patients were monitored during a 14-day antibiotic treatment and a control phase, measuring serum and sputum levels of MPO and ECP.
Potential Biases
Potential observer bias was minimized by having a different investigator than the treating physician.
Limitations
The study was not originally designed as a placebo-controlled trial, and the small sample size may limit the generalizability of the findings.
Participant Demographics
Three males and seven females aged 14 to 44 years, with a mean age of 24 years.
Statistical Information
P-Value
p<0.006
Statistical Significance
p<0.008
Want to read the original?
Access the complete publication on the publisher's website